Inclusion and exclusion criteria and search strategy* for studies investigating the use of noradrenergic treatments in neurodegenerative conditions
| Inclusion criteria | Exclusion criteria |
| Study published between 1980 and 22 December 2021 | Study published prior to 1980 |
| Peer reviewed | Editorials, review articles, letters, or case reports |
| Prospective trial | Conference abstracts |
| Placebo controlled | No placebo group |
| n>1 | Single dose studies |
| Any age | Not in English |
| Study includes predominantly patients with the included diagnoses (or subgroup analysis including patients with the included diagnoses) | Poorly defined patient cohort for example, ‘dementia’ |
| Study reports either a change in recognised score of cognition and/or psychological/psychiatric symptoms/behaviour | Data not accessible, including after request from authors if necessary |
| For studies reporting duplicated data, the most recent or most comprehensive publication to be indexed | Duplicate data |
| English language | |
| Study of drug with principally noradrenergic action |
*Search was done using the following terms ($is used as a truncation command): ((Alzheimer$ or Parkinson$ or “Lewy bod$” or “Frontotemporal d$” or “progressive supranuclear palsy” or “mild cognitive impairment”) and (cogniti$ or behav$ or psychiatric or psychological or memory or attention) and (noradren$ or norepineph$ or epineph$ or adrenergic or “vesicular monoamine transporter inhibitor” or catechol-O-methyltransferase or “Phenylalanine hydroxylase inhibitor” or “Tyrosine hydroxylase inhibitor” or "Aromatic L-amino acid decarboxylase inhibitor” or “Dopamine-beta-hydroxylase inhibitor” or “Phenylethanolamine N-methyltransferase” or guanfacine or atomoxetine or methylphenidate or clonidine or yohimbine or prazosin or mirtazapine) and (trial or control$ or experimental or placebo).mp.)